Intelligent Bio Solutions (INBS) Convertible Debt (2022 - 2023)
Intelligent Bio Solutions (INBS) recorded quarterly Convertible Debt of $389361.0 in Q1 2023, down 25.65% quarter-over-quarter from $523703.0 in Q4 2022.
Intelligent Bio Solutions (INBS) Convertible Debt (2022 - 2023) Analysis & Trends
Intelligent Bio Solutions' Convertible Debt history runs 2 years deep, the most recent figure standing at $389361.0 for Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 159.05 Bn | 152.40 Bn | 6.27 Bn |
| 2 | Stryker | 120.42 Bn | 117.54 Bn | 3.81 Bn |
| 3 | Medtronic | 105.07 Bn | 96.90 Bn | 5.76 Bn |
| 4 | Boston Scientific | 72.63 Bn | 71.41 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.71 Bn | 47.03 Bn | 1.29 Bn |
| 6 | Dexcom | 30.18 Bn | 29.06 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 30.13 Bn | 28.06 Bn | 1.98 Bn |
| 8 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 9 | Steris | 20.88 Bn | 20.46 Bn | 697.10 Mn |
| 10 | Intelligent Bio Solutions | 12.67 Mn | 11.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 389,361.00 |
| Dec 31, 2022 | 523,703.00 |